Cell Death and Disease (Apr 2022)

Integrated DNA and RNA sequencing reveals early drivers involved in metastasis of gastric cancer

  • Jieyun Zhang,
  • Fatao Liu,
  • Yanan Yang,
  • Nuoya Yu,
  • Xiaoling Weng,
  • Yue Yang,
  • Zhe Gong,
  • Shenglin Huang,
  • Lu Gan,
  • Sijie Sun,
  • Xiaowei Zhang,
  • Yiwei Gong,
  • Yun Liu,
  • Weijian Guo

DOI
https://doi.org/10.1038/s41419-022-04838-1
Journal volume & issue
Vol. 13, no. 4
pp. 1 – 12

Abstract

Read online

Abstract Gastric cancer (GC) is the second cause of cancer-related death and metastasis is an important cause of death. Considering difficulties in searching for metastatic driver mutations, we tried a novel strategy here. We conducted an integrative genomic analysis on GC and identified early drivers lead to metastasis. Whole-exome sequencing (WES), transcriptomes sequencing and targeted-exome sequencing (TES) were performed on tumors and matched normal tissues from 432 Chinese GC patients, especially the comparative analysis between higher metastatic-potential (HMP) group with T1 stage and lymph-node metastasis, and lower metastatic-potential (LMP) group without lymph-nodes or distant metastasis. HMP group presented higher mutation load and heterogeneity, enrichment in immunosuppressive signaling, more immune cell infiltration than LMP group. An integrated mRNA-lncRNA signature based on differentially expressed genes was constructed and its prognostic value was better than traditional TNM stage. We identified 176 candidate prometastatic mutations by WES and selected 8 genes for following TES. Mutated TP53 and MADCAM1 were significantly associated with poor metastasis-free survival. We further demonstrated that mutated MADCAM1 could not only directly promote cancer cells migration, but also could trigger tumor metastasis by establishing immunosuppressive microenvironment, including promoting PD-L1-mediated immune escape and reprogramming tumor-associated macrophages by regulating CCL2 through Akt/mTOR axis. In conclusion, GCs with different metastatic-potential are distinguishable at the genetic level and we revealed a number of potential metastatic driver mutations. Driver mutations in early-onset metastatic GC could promote metastasis by establishing an immunosuppressive microenvironment. This study provided possibility for future target therapy of GC.